Catch up on the latest
Glucotrack news
Stay informed. Discover the newest updates and developments at Glucotrack and the steps we’re taking to revolutionize glycemic management.
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference RUTHERFORD, N.J., March 19, 2025 — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that safety and performance data from its…
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member
Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology RUTHERFORD, N.J., Feb. 26, 2025 — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Guillermo Umpierrez, MD, CDCES, FACE, MACP,…
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Rutherford, NJ., Feb. 04, 2025 — Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is…
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
The study met its primary endpoint with no procedure or device related serious adverse events reported RUTHERFORD, N.J., Feb. 04, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the successful completion of its first…
Glucotrack Announces Reverse Stock Split
1-for-20 reverse stock split to become effective as of the opening of trading on February 4, 2025 RUTHERFORD, N.J., Jan. 30, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect…
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes RUTHERFORD, N.J., Jan. 29, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes,…
Glucotrack Announces ISO 13485:2016 Certification
ISO Certification highlights commitment to quality for continuous blood glucose monitor RUTHERFORD, N.J., Jan. 21, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has received ISO 13485:2016 certification from the British…
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes RUTHERFORD, N.J., Jan. 15, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that…
Glucotrack to Present at TechBio Showcase™ 2025
Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetes RUTHERFORD, N.J., Jan. 07, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it is presenting…
GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
Feasibility study underway for the Company’s novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeks Rutherford, NJ, Dec. 03, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, has announced…